Literature DB >> 20820086

Early age renal synovial sarcoma.

Alfredo Ernesto Romero-Rojas1, Julio Alexander Díaz-Pérez, Oscar Alberto Messa-Botero, Fabían Enrique Neira-Mejia.   

Abstract

OBJECTIVE: We report a primary renal Synovial Sarcoma (SS) case and analyze its features.
METHOD: A 15 year old male presented with left abdominal mass and weight loss. CT scan images showed a 13 cm mass located in the lower pole of the left kidney. Renal biopsy recognized an undifferentiated neoplasm, the immunohistochemistry suggesting the probability of neuroectodermic primitive tumor versus SS. Chemotherapy and radical nephrectomy were carried out. Pathological study showed a big multilobulated necrotic tumor 22 x 13 x 12.5 cm. Histopathological study demonstrated a neoplasm composed by immature cells. Currently, patient has survived 1,8 years. A structured bibliographical search was performed in the Medline, Imbiomed and Scielo databases.
RESULTS: The final immunohistochemistry studies gave the diagnosis of poorly differentiated renal SS small cell variety.
CONCLUSION: The renal SS is extremely infrequent, with less than 40 cases reported, of which this case reports the earlier age. These tumors, when located in the kidney, represent a great diagnostic challenge that requires adequate clinical, radiological, surgical, and pathological correlation for appropriate diagnosis and treatment.

Entities:  

Mesh:

Year:  2010        PMID: 20820086

Source DB:  PubMed          Journal:  Arch Esp Urol        ISSN: 0004-0614            Impact factor:   0.436


  2 in total

1.  Primary Renal Synovial Sarcoma and Clinical and Pathological Findings: a Systematic Review.

Authors:  Leandro Blas; Javier Roberti
Journal:  Curr Urol Rep       Date:  2021-03-11       Impact factor: 3.092

Review 2.  Primary synovial sarcoma of the kidney: a case report of complete pathological response at a Lebanese tertiary care center.

Authors:  Alissar El Chediak; Deborah Mukherji; Sally Temraz; Samer Nassif; Sara Sinno; Rami Mahfouz; Ali Shamseddine
Journal:  BMC Urol       Date:  2018-05-11       Impact factor: 2.264

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.